AATec Medical starts collaboration with the German Federal Agency for Disruptive Innovation SPRIND for alpha-1 antitrypsin
SPRIND supports the development of ATL-105 for the treatment of viral respiratory diseases in various disease models
13-Feb-2024 -
AATec Medical GmbH (AATec), a biotech company developing a multi-product platform based on recombinant alpha-1 antitrypsin (AAT), announces the start of its collaboration with the German Federal Agency for Disruptive Innovations (SPRIND). This project is a key step in the development of the ...
acute respiratory disease syndrome
asthma
chronic obstructive pulmonary disease
+2